natgillin/translations-raw huggingface dataset:
(95 % CI) Subjects (%) achieving: HbA1c < 7 % (LOCF) Adjusted for baseline Body weight (kg) (LOCF) Baseline (mean) Change from baseline Difference from placebo c 
(95 % IZ) Preiskovanci (%), ki so dosegli: HbA1c < 7 % (LOCF) Prilagojeno za izhodišče Telesna masa (kg) (LOCF) Izhodiščno (povprečje) Sprememba od izhodišča Razlika v primerjavi s placebom c
LOCF: Last observation carried forward 
LOCF: Prenos zadnjega opažanja (pred rešilnim zdravljenjem za preiskovance s takšnim zdravljenjem) [Last observation carried forward]
(95 % CI) Subjects (%) achieving: HbA1c < 7 % Adjusted for baseline Body weight (kg) Baseline (mean) Change from baseline Difference from placebo c 
(95 % IZ) Preiskovanci (%), ki so dosegli: HbA1c < 7% Prilagojeno za izhodišče Telesna masa (kg) Izhodišče (povprečje) Sprememba od izhodišča Razlika glede na placebo c
In an add-on to insulin study, episodes of major hypoglycaemia were reported in 0.5 % and 1.0 % of subjects treated with dapagliflozin 10 mg plus insulin at Weeks 24 and 104, respectively, and in 0.5 % of subjects treated with placebo plus insulin groups at Weeks 24 and 104. 
V študiji dodatka k insulinu so hude hipoglikemije do 24. oziroma 104. tedna zabeležili pri 0,5 % oziroma 1,0 % prejemnikov kombinacije 10 mg dapagliflozina in insulina ter pri 0,5 % prejemnikov kombinacije placeba in insulina.
The mean change from baseline in HbA1c at 24 weeks was -0.44 % and -0.33 %, for dapagliflozin 10 mg and placebo, respectively. 
Povprečna sprememba HbA1c od izhodišča za 10 mg dapagliflozina je bila 24. teden -0,44 % in -0,33 % za placebo.
Columns 1 and 2, HbA1c analysed using LOCF (see footnote d); Columns 3 and 4, HbA1c analysed using LRM (see footnote e) Least squares mean adjusted for baseline value LOCF: Last observation (prior to rescue for rescued subjects) carried forward LRM: Longitudinal repeated measures analysis p-value < 0.0001 versus placebo + oral glucose-lowering medicinal product(s) 
Stolpca 1 in 2, HbA1c analiziran po metodi LOCF (glejte opombo d), stolpca 3 in 4, HbA1c analiziran z metodo LRM (glejte opombo e)
Pack sizes of 14, 28 and 98 film-coated tablets in non-perforated calendar blisters Pack sizes of 30x1 and 90x1 film-coated tablets in perforated unit dose blisters 
Velikosti pakiranj s 14, 28 in 98 filmsko obloženimi tabletami v neperforiranih koledarskih pretisnih omotih.
a) in an active-controlled study comparing dapagliflozin to glipizide as add-on to metformin 
Rezultati z zdravilno učinkovino kontrolirane študije, ki je primerjala dapagliflozin z glipizidom kot dodatkom k metforminu po 52 tednih (LOCF
• Edistride 5 mg film-coated tablets are yellow and round with diameter of 0.7 cm. 
• Tablete zdravila Edistride 5 mg filmsko obložene tablete so rumene barve, okrogle oblike s premerom 0,7 cm. Na eni strani imajo vtisnjeno oznako "5" in na drugi strani "1427".
Fifty percent of subjects were on insulin monotherapy at baseline; 50 % were on 1 or 2 oral glucose-lowering medicinal product(s) in addition to insulin: Of this latter group, 80 % were on metformin alone, 12 % were on metformin plus sulphonylurea therapy, and the rest were on other oral glucose-lowering medicinal products. 
Petdeset odstotkov preiskovancev je bilo izhodiščno na monoterapiji z insulinom; 50 % jih je poleg insulina jemalo 1 ali 2 peroralna antidiabetika.
Talk to your doctor if you would like to or are breast-feeding before taking this medicine. 
Če dojite ali želite dojiti, se posvetujte s svojim zdravnikom pred jemanjem tega zdravila.
Edistride 5 mg film-coated tablets Edistride 10 mg film-coated tablets 
Edistride 5 mg filmsko obložene tablete Edistride 10 mg filmsko obložene tablete
Volume depletion b,e 
pomanjkanje volumna b,e žeja diabetična ketocidoza
Edistride 5 mg film-coated tablets Edistride 10 mg film-coated tablets dapagliflozin 
Edistride 5 mg filmsko obložene tablete Edistride 10 mg filmsko obložene tablete dapagliflozin
Each tablet contains dapagliflozin propanediol monohydrate equivalent to10 mg dapagliflozin. 
Ena tableta vsebuje dapagliflozin-propandiol monohidrat, kolikor ga ustreza 10 mg dapagliflozina.
a) of a placebo-controlled study of dapagliflozin as monotherapy 
Rezultati s placebom kontrolirane študije dapagliflozina kot monoterapije po 24 tednih (LOCF
Edistride 5 mg film-coated tablets Each tablet contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin. 
Edistride 5 mg filmsko obložene tablete Ena tableta vsebuje dapagliflozin-propandiol monohidrat, kolikor ga ustreza 5 mg dapagliflozina.
Edistride 10 mg film-coated tablets Each tablet contains dapagliflozin propanediol monohydrate equivalent to 10 mg dapagliflozin. 
Edistride 10 mg filmsko obložene tablete Ena tableta vsebuje dapagliflozin-propandiol monohidrat, kolikor ga ustreza 10 mg dapagliflozina.
Nocturia Renal impairment 
*,f nikturija okvara ledvic
Sulphonylurea (glimepiride 
Urejenost glikemije
Mean daily insulin dose (IU) Baseline (mean) Change from baseline Difference from placebo c 
Izhodišče (povprečje) Sprememba od izhodišča Razlika glede na placebo c
Use alternative methods to monitor glycaemic control. 
Pri teh bolnikih je treba za spremljanje urejenosti glikemije uporabljati druge metode.
*,b,d 
*,b,d glivična okužba
(95 % CI) Subjects (%) achieving: HbA1c < 7 % Adjusted for baseline 
(95 % IZ) Preiskovanci (%), ki so dosegli: HbA1c < 7 % Prilagojeno za izhodišče Telesna masa (kg) Izhodišče (povprečje) Sprememba od izhodišča Razlika v primerjavi s placebom c
Slovenija AstraZeneca UK Limited 
Lietuva UAB AstraZeneca Lietuva
Dapagliflozin 10 mg 
Glimepirid 4 mg/dan
• A valid GMP compliance statement for the manufacturer of the absorbable collagen sponge (ACS), fulfilling the requirements set out in Article 46 of Directive 2001/83/EC. 
• veljavna izjava o skladnosti proizvajalca absorpcijske kolagenske gobe z dobro proizvodno prakso, ki izpolnjuje zahteve iz člena 46 Direktive 2001/83/ES.
For the suspension to be lifted, the Marketing Authorisation Holder for InductOs shall ensure that the following condition is fulfilled: 
Za preklic začasnega umika mora imetnik dovoljenja za promet z zdravilom InductOs zagotoviti, da je izpolnjen naslednji pogoj:
Annex II Conditions for lifting the suspension of the marketing authorisation(s) 
Priloga II
The full EPAR and risk management plan summary for Pemetrexed Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Pemetreksed Hospira sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Pemetrexed Hospira. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pemetreksed Hospira.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed Hospira has been shown to be comparable to Alimta. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Pemetreksed Hospira primerljivo z zdravilom Alimta.
What measures are being taken to ensure the safe and effective use of Pemetrexed Hospira? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pemetreksed Hospira?
The Committee recommended that Pemetrexed Hospira be approved for use in the EU. 
Priporočil je, da se zdravilo Pemetreksed Hospira odobri za uporabo v EU.
This means that Pemetrexed Hospira is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Alimta.
Because Pemetrexed Hospira is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Pemetreksed Hospira generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
A risk management plan has been developed to ensure that Pemetrexed Hospira is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Pemetreksed Hospira je bil pripravljen načrt obvladovanja tveganj.
Pemetrexed Hospira is a cancer medicine used to treat two types of lung cancer: 
Pemetreksed Hospira je zdravilo proti raku, ki se uporablja za zdravljenje dveh vrst pljučnega raka:
What are the benefits and risks of Pemetrexed Hospira? 
Kakšne so koristi in tveganja, povezani z zdravilom Pemetreksed Hospira?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed Hospira, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Other information about Pemetrexed Hospira 
Druge informacije o zdravilu Pemetreksed Hospira
For practical information about using Pemetrexed Hospira, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Pemetreksed Hospira naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
What is Pemetrexed Hospira and what is it used for? 
Kaj je zdravilo Pemetreksed Hospira in za kaj se uporablja?
It is not intended to provide practical advice on how to use Pemetrexed Hospira. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed Hospira. 
Da bi zmanjšali neželene učinke, morajo bolniki med zdravljenjem z zdravilom Pemetreksed Hospira jemati kortikosteroid (vrsto zdravila, ki ublaži vnetje) in folno kislino (vrsto vitamina) ter prejemati injekcije vitamina B12.
Pemetrexed Hospira is a ‘generic medicine'. 
Zdravilo Pemetreksed Hospira je „generično zdravilo“.
For more information about treatment with Pemetrexed Hospira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Pemetreksed Hospira preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The active substance in Pemetrexed Hospira, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'. 
Zdravilna učinkovina v zdravilu Pemetreksed Hospira, pemetreksed, je citotoksik (zdravilo, ki uničuje celice, ki se delijo, kot na primer rakave celice) iz skupine „antimetabolitov“.
When Pemetrexed Hospira is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose. 
Kadar se zdravilo Pemetreksed Hospira daje v kombinaciji s cisplatinom, je treba pred odmerkom cisplatina ali po njem bolniku dati tudi „antiemetično“ zdravilo (za preprečevanje bruhanja) in tekočino (za preprečevanje dehidracije).
Pemetrexed Hospira is available as a powder that is made up into a solution for infusion (drip) into a vein. 
Zdravilo Pemetreksed Hospira je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalna infuzija) v veno.
Why is Pemetrexed Hospira approved? 
Zakaj je bilo zdravilo Pemetreksed Hospira odobreno?
Pemetrexed Hospira pemetrexed 
Pemetreksed Hospira pemetreksed
How is Pemetrexed Hospira used? 
Kako se zdravilo Pemetreksed Hospira uporablja?
Pemetrexed Hospira contains the active substance pemetrexed. 
Zdravilo Pemetreksed Hospira vsebuje zdravilno učinkovino pemetreksed.
No additional studies were needed as Pemetrexed Hospira is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta. 
Ker je zdravilo Pemetreksed Hospira generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Alimta, niso bile potrebne nobene dodatne študije.
How has Pemetrexed Hospira been studied? 
Kako je bilo zdravilo Pemetreksed Hospira raziskano?
How does Pemetrexed Hospira work? 
Kako zdravilo Pemetreksed Hospira deluje?
Everyone is different. 
Vsi ljudje se med seboj razlikujejo.
Hands should be washed. 
Roke morate umiti.
It is recombinant meaning it is not made from human or animal tissue. 
Rekombinanten pomeni, da ni narejen iz človeškega ali živalskega tkiva.
Acute critical illness 
Akutne kritične bolezni
Long-term safety data are still limited. 
Podatkov o dolgoročni varnosti zdravila je še vedno malo.
Patients with PWS and one or more of these risk factors may be at greater risk. 
Bolniki s PWS in enim ali več dejavnikov tveganja so bolj ogroženi.
This can start during either adult life or it can continue from childhood. 
To se lahko začne v odrasli dobi ali se nadaljuje iz otroštva.
Do not attempt to inject unless you are sure you understand the procedure and requirements for the injection. 
Ne poskušajte si ga injicirati, če niste prepričani, da razumete postopek in zahteve glede injiciranja.
• and tell your doctor if you have an active tumour (cancer). 
• Povejte svojemu zdravniku, če imate aktivni tumor (raka).
10 A-6336 Langkampfen Austria 
10 A-6336 Langkampfen Avstrija
This presentation is intended for multiple use. 
Ta oblika je namenjena za večkratno uporabo.
You are now ready to inject the dose. 
Zdaj ste pripravljeni za injiciranje odmerka.
Contains benzyl alcohol. 
Vsebuje benzilalkohol.
Date of first authorisation: 12 April 2006 Date of latest renewal: 12 April 2011 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 12. april 2006 Datum zadnjega podaljšanja: 12. april 2011
A decrease in peripheral vascular resistance may contribute to this effect. 
Zmanjšanje perifernega žilnega upora lahko pripomore k temu učinku.
The powder is white. 
Prašek je bel.
• Treatment should be continued until you have stopped growing. 
• Zdravljenje naj se nadaljuje, dokler ne nehate rasti.
- Use the solution immediately. 
- Raztopino uporabite takoj.
Please read the instructions carefully and follow them step by step. 
Prosimo, da skrbno preberete navodila in jih upoštevate.
DATE OF REVISION OF THE TEXT <{MM/YYYY}> 
DATUM ZADNJE REVIZIJE BESEDILA <{MM/LLLL}>
Do not inject into this site; withdraw the needle and repeat this step. 
Zdravila ne injicirajte na to mesto; iglo izvlecite in ta korak ponovite.
• synthetic adrenal hormones (corticosteroids). 
• sintetične adrenalne hormone (kortikosteroide).
• ciclosporin (a medicine that weakens the immune system after transplantation), 
• ciklosporin (zdravilo, ki po presaditvi oslabi imunski sistem),
• If you were small or too light at birth. 
• če ste bili ob rojstvu premajhni ali prelahki.
In adults 
Pri odraslih
Turner syndrome is a genetic disorder in girls that can affect growth - your doctor will have told you if you have this. 
Turnerjev sindrom je genetska motnja pri deklicah, ki lahko vpliva na rast - če imate to motnjo, vam je to povedal zdravnik.
As kidneys lose their ability to function normally, this can affect growth. 
Ker ledvice izgubljajo svojo sposobnost normalnega delovanja, lahko to vpliva na vašo rast.
Based on this information, these types of patients should not be treated with somatropin. 
Na podlagi teh informacij se ti bolniki ne smejo zdraviti s somatropinom.
Women may require higher doses than men. 
Pri ženskah so morda potrebni večji odmerki kot pri moških.
In particular, inform your doctor if you are taking or have recently taken any of the following medicines. 
Še posebej pa zdravnika obvestite, če jemljete ali ste pred kratkim jemali katero koli od naslednjih zdravil.
• If you are not growing properly and you do not have enough of your own growth hormone. 
• če ne rastete pravilno in nimate dovolj lastnega rastnega hormona,
This can be tested by your doctor and if necessary your doctor will prescribe the adequate treatment. 
To lahko zdravnik testira in po potrebi predpiše ustrezno zdravljenje.
Treatment should be discontinued after the first year if you are not responding or if you have reached your final height and stopped growing. 
Zdravljenje je treba prekiniti po prvem letu, v katerem se ne odzivate na zdravljenje ali če ste dosegli svojo končno višino in nehali rasti.
It is best to use your growth hormone regularly. 
Najbolje je, da rastni hormon uporabljate redno.
If you forget to use a dose, have your next injection at the usual time the next day. 
Če ste si pozabili dati odmerek, si injicirajte naslednjo injekcijo naslednji dan ob običajnem času.
• If you were too small or too light at birth and are aged between 9 and 12 years, ask your doctor for specific advice relating to puberty and treatment with this medicine. 
• Če ste bili ob rojstvu premajhni ali prelahki in ste stari med 9 in 12 leti, vprašajte zdravnika za nasvet, ki se nanaša na puberteto, in zdravljenje s tem zdravilom.
Small for gestational age 
Majhnost za gestacijsko starost
When treatment with somatropin is started this deficit is rapidly corrected. 
Po začetku zdravljenja s somatropinom se primanjkljaj hitro popravi.
Bedtime is a good time because it is easy to remember. 
Primeren čas je pred spanjem, saj si ga je lahko zapomniti.
Reconstitution should be performed in accordance with good practice rules, particularly in the respect of asepsis. 
Rekonstrukcijo je treba opraviti skladno s pravili dobre prakse, zlasti glede aseptičnih pogojev:
• medicines to control epilepsy (anticonvulsants), 
• zdravilo za nadzor epilepsije (antikonvulzive),
Physical capacity 
Telesna zmogljivost
With your other hand, hold the syringe as you would a pencil. 
Z drugo roko držite brizgo, kot bi držali svinčnik.
It may cause toxic reactions and allergic reactions in infants and children up to 3 years old. 
Lahko povzroči toksične in alergijske reakcije pri dojenčkih in otrocih do 3 leta starosti.
Insert the needle into the pinched skin at an angle of 45° to 90°. 
Zabodite iglo v stisnjeno kožo pod kotom 45 do 90 °.
You might feel shaky, sweaty, sleepy or “not yourself”, and you might faint. 
Zato se boste morda tresli, se potili, boste zaspani in »ne boste čisto pravi«, lahko pa tudi omedlite.
The minimum effective dose should be used. 
Uporabljati je treba najnižji učinkoviti odmerek.
You should not use Omnitrope if you are pregnant or trying to become pregnant. 
Zdravila Omnitrope ne smete uporabljati, če ste noseči ali želite zanositi.
Dosage should be monitored every 6 months. 
Odmerek je treba vsakih 6 mesecev preveriti.
Scoliosis may progress in any child during rapid growth. 
Napreduje lahko pri kateremkoli otroku v obdobju hitre rasti.
The accuracy of the growth hormone dose should therefore be controlled every 6 months. 
Ustreznost odmerka rastnega hormona je treba zato preverjati vsakih šest mesecev.
Your excessive fat will decrease and your reduced muscle mass will improve. 
Odvečna maščoba se zmanjša in zmanjšana mišična masa se bo izboljšala.
Somatropin may reduce insulin sensitivity. 
Somatropin lahko zmanjša občutljivost na insulin.
Your blood sugar level could fall too low and later rise too high. 
Raven sladkorja v krvi bi lahko najprej preveč padla in se nato preveč povečala.
This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. 
To pomeni, da obstaja nevarnost, da bodo ženske, še posebej tiste, ki prejemajo peroralno nadomestno estrogensko zdravljenje, dobile premajhen odmerek, moški pa prevelikega.
• if you are allergic (hypersensitive) to somatropin or to any of the other ingredients of Omnitrope. 
• če ste alergični (preobčutljivi) na somatropin ali katero koli sestavino zdravila Omnitrope.
• Experience in patients above 80 years is limited. 
• Izkušnje pri bolnikih, starih več kot 80 let, so omejene.
Growth hormone can help you grow taller if you have not been able to catch up or maintain normal growth by 4 years of age or later. 
Rastni hormon vam pomaga zrasti, če niste uspeli dohiteti vrstnikov ali vzdrževati normalne rasti pri starosti 4 leta ali več.
Do not shake; this may cause denaturation of the active substance. 
Ne stresajte; to lahko povzroči denaturacijo zdravilne učinkovine.
* produced in Escherichia coli by recombinant DNA technology. 
* Izdelan iz celic Escherichia coli s tehnologijo rekombinantne DNA.
Your doctor may need to adjust the dose of these medicines or the dose of somatropin. 
Morda bo moral vaš zdravnik prilagoditi odmerek teh zdravil ali odmerek somatropina.
• and tell your doctor if Omnitrope has been prescribed to stimulate growth but you have already stopped growing (closed epiphyses). 
• Povejte zdravniku, če vam je bilo zdravilo Omnitrope predpisano za spodbujanje rasti, a ste že prenehali rasti (zaprte epifize).
However, no link has been made between these cases and treatment with Omnitrope. 
Vendar pa povezave med temi primeri in zdravljenjem z zdravilom Omnitrope niso ugotovili.
It should be reconstituted with a transfer set as recommended in the information provided with the transfer set. 
Raztopino je treba pripraviti s setom za prenos, kot je to priporočeno v informacijah, priloženih setu za prenos.
Muscle strength and physical exercise capacity are improved after long-term treatment with somatropin. 
Mišična moč in telesna zmogljivost se izboljšata po dolgotrajnem zdravljenju s somatropinom.
The maximum recommended daily dose should not be exceeded (see section 4.2). 
Največjega priporočenega dnevnega odmerka se ne sme prekoračiti (glejte poglavje 4.2).
If on repeated measurements IGF-I levels exceed +2 SD compared to references for age and pubertal status, the IGF-I / IGFBP-3 ratio could be taken into account to consider dose adjustment. 
Če pri ponovljenih meritvah ravni IGF-I presegajo +2 SD v primerjavi z referenčnimi vrednostmi za starost in puberteto, se za preučitev prilagoditve odmerkov lahko upošteva razmerje IGF-I/IGFBP-3.
Wait for the area to dry. 
Počakajte, da se predel posuši.
If necessary, glucocorticoid replacement should be initiated. 
Po potrebi je treba začeti z nadomeščanjem glukokortikoidov.
Do not change the dosage and treatment schedule without consulting your doctor. 
Odmerka in režima zdravljenja ne spreminjajte, ne da bi se prej posvetovali z zdravnikom.
Neoplasms Benign, Malignant and Unspecified (including cysts and polyps) 
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
But it is unknown if these 2 pathologies are more frequent or not while treated with somatropin. 
Vendar ni znano, ali sta ti dve bolezenski stanji pogostejši pri zdravljenju s somatropinom ali ne.
• If you have Turner syndrome. 
• če imate Turnerjev sindrom.
8°C in the original package. 
2 °C-8 °C v originalni ovojnini.
The clinical relevance of these findings may be limited. 
Klinična pomembnost teh izsledkov je lahko omejena.
Growth hormone will help you grow taller if you are still growing, and will also improve your body composition. 
Rastni hormon vam pomaga če še vedno rastete, izboljša pa tudi sestavo telesa.
If you are about to have, or have had, a major operation, or go into hospital for any reason, tell your doctor and remind the other doctors you are seeing that you use growth hormone. 
Če načrtujete ali ste imeli veliko operacijo ali če greste zaradi kateregakoli razloga v bolnišnico, povejte svojemu zdravniku in opomnite vse druge zdravnike, da uporabljate rastni hormon.
Also see section 4.4 for statements regarding diabetes mellitus and thyroid disorder and section 4.2 for statement on oral oestrogen replacement therapy. 
Glejte tudi poglavje 4.4 o ugotovitvah, ki se nanašajo na diabetes mellitus in motnje delovanja ščitnice, ter poglavje 4.2 o ugotovitvah, ki se nanašajo na peroralno estrogensko nadomestno zdravljenje.
Somatropin must not be used for growth promotion in children with closed epiphyses. 
Somatropina se ne sme uporabljati za pospeševanje rasti otrok z zaprtimi epifizami.